Login to Your Account



Syntonix, Boehringer Enter $63M Inhaled Peptide Deal

By Karen Pihl-Carey


Monday, October 24, 2005
For the second time this year, an international drug company is showing a strong interest in Syntonix Pharmaceuticals Inc.'s Synfusion and Transceptor technologies - this time to the tune of up to $63 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription